Madrigal registers two resmetirom studies: Phase 1b in MASH/HFpEF and Phase 4 drug-interaction trial
Madrigal Pharmaceuticals has two resmetirom studies listed as recruiting on ClinicalTrials.gov, one testing the drug in patients with heart failure and one checking interactions with diabetes medicines.
Madrigal Pharmaceuticals has two resmetirom-related studies listed as recruiting, both last updated October 16, 2026.
- A Phase 1b trial (NCT07830758) is testing resmetirom in adults with MASH and heart failure with preserved ejection fraction. The randomized, double-blind, placebo-controlled study will assign participants 2:1 to resmetirom or placebo for 24 weeks.1 The study was first posted September 21, 2026 and last updated October 16, 20261, with an estimated enrollment of 90 participants.1
- A Phase 4 open-label study (NCT07848191) is evaluating Rezdiffra (resmetirom) safety when combined with diabetes drugs pioglitazone (Actos) and dapagliflozin (Farxiga) in MASH patients with F2-F3 fibrosis. The study will assess safety and tolerability of resmetirom used alongside Actos/pioglitazone and Farxiga/dapagliflozin, administered per their approved labeling.2 The trial plans approximately 25 participants in each of six cohorts, for a maximum enrollment of about 150.2 It started October 7, 2026 and was first posted September 29, 2026.2
Fact check notes
- Imprecise
Madrigal Pharmaceuticals has two resmetirom studies listed as recruiting on ClinicalTrials.gov, one testing the drug in patients with heart failure and one checking interactions with diabetes medicines.
Both studies are indeed recruiting, and one does involve HFpEF patients. However, the second study is framed as a safety/tolerability study of concomitant use, not specifically an 'interaction' study in the pharmacokinetic sense. - Imprecise
Madrigal registers two resmetirom studies: Phase 1b in MASH/HFpEF and Phase 4 drug-interaction trial
The Phase 4 study (NCT07848191) is described in the source as a safety/tolerability study of resmetirom used in combination with approved diabetes therapies (pioglitazone, dapagliflozin), not explicitly as a 'drug-interaction trial.' Otherwise the headline correctly identifies two recruiting resmetirom studies, one Phase 1b in MASH/HFpEF and one Phase 4 combination study. - Checker's noteThe headline and opening summary describe the Phase 4 study (NCT07848191) as a 'drug-interaction trial' or testing drug 'interactions,' but the source frames it as a safety/tolerability study of resmetirom used concomitantly with approved diabetes medications, not a formal pharmacokinetic interaction study.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.